Physician profile
Daniel M Rosenberg
NPI 1629038526
$13,479.03
in general payments reported to CMS, 2019-2025
57 companies · $2,209 in 2025
The $2,209 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $912 · 2020: $971 · 2021: $1,226 · 2022: $4,596 · 2023: $1,583 · 2024: $1,983 · 2025: $2,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,773.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,289.34 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,512.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,373.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $711.54 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $654.74 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $615.99 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $595.68 | 2019-2025 | Jardiance, Ofev, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $254.56 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $241.75 | 2022-2025 | |
| Axsome Therapeutics, INC. | $240.28 | 2025 | Auvelity, Symbravo |
| Amgen INC. | $234.52 | 2021-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $232.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $222.11 | 2022-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $206.08 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Dexcom, INC. | $145.88 | 2021-2024 | Dexcom G6 Transmitter |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.